Tadataka Yamada - Agilent Technologies Independent Director
| A Stock | USD 137.04 2.55 1.83% |
Director
Dr. Tadataka Yamada, M.D., is Independent Director of Agilent Technologies, Inc. r. Yamada is currently a Venture Partner on the Life Sciences team of Frazier Healthcare Partners, a healthcarefocused investment firm. From June 2011 to June 2015, Dr. Yamada served as the Chief Medical and Scientific Officer of Takeda Pharmaceuticals International, Inc., a researchbased global pharmaceutical company since 2011.
| Age | 74 |
| Tenure | 13 years |
| Professional Marks | Ph.D |
| Address | 5301 Stevens Creek Boulevard, Santa Clara, CA, United States, 95051 |
| Phone | 800 227 9770 |
| Web | https://www.agilent.com |
Tadataka Yamada Latest Insider Activity
Tracking and analyzing the buying and selling activities of Tadataka Yamada against Agilent Technologies stock is an integral part of due diligence when investing in Agilent Technologies. Tadataka Yamada insider activity provides valuable insight into whether Agilent Technologies is net buyers or sellers over its current business cycle. Note, Agilent Technologies insiders must abide by specific rules, including filing SEC forms every time they buy or sell Agilent Technologies'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Tadataka Yamada over six months ago Acquisition by Tadataka Yamada of 2352 shares of Agilent Technologies subject to Rule 16b-3 |
Agilent Technologies Management Efficiency
The company has return on total asset of 0.0785 % which means that for every 100 dollars spent on assets, it generated a profit of $0.0785. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2095 %, implying that it made 0.2095 on every $100 invested by shareholders. Agilent Technologies' management efficiency ratios could be used to measure how well Agilent Technologies manages its routine affairs as well as how well it operates its assets and liabilities. At present, Agilent Technologies' Return On Tangible Assets are projected to increase slightly based on the last few years of reporting. The current year's Return On Capital Employed is expected to grow to 0.14, whereas Return On Assets are forecasted to decline to 0.05. At present, Agilent Technologies' Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 283.8 M, whereas Total Assets are forecasted to decline to about 9.3 B.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| John Workman | CONMED | 69 | |
| Megan CPA | Inspire Medical Systems | N/A | |
| Henry Anhalt | Tandem Diabetes Care | 54 | |
| Antoine Papiernik | Shockwave Medical | 52 | |
| Fred Cohen | Tandem Diabetes Care | 60 | |
| Jesse Treu | Tandem Diabetes Care | 67 | |
| Jerry Griffin | Inspire Medical Systems | 76 | |
| Gilbert Kliman | Glaukos Corp | 61 | |
| Richard Valencia | Tandem Diabetes Care | 56 | |
| Daniel Levangie | Insulet | 64 | |
| Christopher Twomey | Tandem Diabetes Care | 58 | |
| Susan Vogt | Anika Therapeutics | 66 | |
| Gary Ellis | Inspire Medical Systems | 64 | |
| Walter Wang | Penumbra | 47 | |
| James Mullen | Insulet | 58 | |
| Jo Golden | CONMED | 69 | |
| Neil Luke | Inspire Medical Systems | N/A | |
| Glenn Larsen | Anika Therapeutics | 62 | |
| Mudit Jain | Inspire Medical Systems | 49 | |
| Chau Khuong | Inspire Medical Systems | 42 | |
| Bridget ORourke | Penumbra | 52 | |
Management Performance
| Return On Equity | 0.21 | ||||
| Return On Asset | 0.0785 |
Agilent Technologies Leadership Team
Elected by the shareholders, the Agilent Technologies' board of directors comprises two types of representatives: Agilent Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Agilent. The board's role is to monitor Agilent Technologies' management team and ensure that shareholders' interests are well served. Agilent Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Agilent Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Philip Binns, Senior Group | ||
| Padraig McDonnell, Senior Vice President and Presidentident - Agilent CrossLab Group | ||
| Daniel Podolsky, Independent Director | ||
| Hans Bishop, Independent Director | ||
| George Scangos, Independent Director | ||
| Sue Rataj, Independent Director | ||
| Jacob Thaysen, Senior Vice President, Agilent, President - Life Sciences and Applied Markets Group | ||
| Darlene Solomon, CTO VP | ||
| Samraat Raha, Senior Vice President, Agilent, President - Diagnostics and Genomics Group | ||
| Mark Doak, Senior Vice President, President - Agilent CrossLab Group | ||
| Paul Clark, Independent Director | ||
| Mala Anand, Independent Director | ||
| Jenipher Dalton, Chief VP | ||
| Robert McMahon, Chief Financial Officer, Senior Vice President | ||
| Ankur Dhingra, Investor Relations | ||
| John Kohl, Senior Officer | ||
| Mikael Dolsten, Independent Director | ||
| Allison Ballmer, Vice President - Strategy and Corporate Development | ||
| Hajime Tada, Interim General Counsel | ||
| James Cullen, Independent Non-Executive Chairman of the Board | ||
| Michael McMullen, CEO and President Director and Member of Executive Committee | ||
| Patrick Kaltenbach, Sr. VP and President of Life Sciences and Applied Markets Group (LSAG) Bus. Unit | ||
| Rodney Gonsalves, Chief Accounting Officer, Vice President, Corporate Controllership | ||
| Henrik AncherJensen, Senior Vice President, Agilent and President - Order Fulfillment | ||
| Dow Wilson, Independent Director | ||
| Diana Chiu, Interim VP | ||
| Heidi Kunz, Independent Director | ||
| Otis Brawley, Independent Director | ||
| Dominique Grau, Senior Vice President of Human Resources and Global Communications | ||
| Susan Rataj, Independent Director | ||
| Heidi Fields, Independent Director | ||
| Michael Tang, Senior Vice President General Counsel, Secretary | ||
| Alicia Rodriguez, Vice President - Investor Relations | ||
| Tadataka Yamada, Independent Director | ||
| Didier Hirsch, CFO and Sr. VP | ||
| Katharine Knobil, Chief Medical Officer. | ||
| Boon Koh, Non-Executive Independent Chairman of the Board | ||
| Robert Herbold, Independent Director | ||
| Yvonne Mackie, MD Europe |
Agilent Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Agilent Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.21 | ||||
| Return On Asset | 0.0785 | ||||
| Profit Margin | 0.18 % | ||||
| Operating Margin | 0.24 % | ||||
| Current Valuation | 41.88 B | ||||
| Shares Outstanding | 293.06 M | ||||
| Shares Owned By Insiders | 0.28 % | ||||
| Shares Owned By Institutions | 92.65 % | ||||
| Number Of Shares Shorted | 4.12 M | ||||
| Price To Earning | 37.55 X |
Pair Trading with Agilent Technologies
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Agilent Technologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Agilent Technologies will appreciate offsetting losses from the drop in the long position's value.Moving together with Agilent Stock
| 0.68 | DRRX | Durect Earnings Call This Week | PairCorr |
Moving against Agilent Stock
| 0.64 | SBFMW | Sunshine Biopharma | PairCorr |
| 0.41 | CUE | Cue Biopharma Buyout Trend | PairCorr |
The ability to find closely correlated positions to Agilent Technologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Agilent Technologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Agilent Technologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Agilent Technologies to buy it.
The correlation of Agilent Technologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Agilent Technologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Agilent Technologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Agilent Technologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Agilent Technologies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For information on how to trade Agilent Stock refer to our How to Trade Agilent Stock guide.Note that the Agilent Technologies information on this page should be used as a complementary analysis to other Agilent Technologies' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Complementary Tools for Agilent Stock analysis
When running Agilent Technologies' price analysis, check to measure Agilent Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Agilent Technologies is operating at the current time. Most of Agilent Technologies' value examination focuses on studying past and present price action to predict the probability of Agilent Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Agilent Technologies' price. Additionally, you may evaluate how the addition of Agilent Technologies to your portfolios can decrease your overall portfolio volatility.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |
Is Agilent Technologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agilent Technologies. If investors know Agilent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agilent Technologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.01) | Dividend Share 0.911 | Earnings Share 4.17 | Revenue Per Share 22.967 | Quarterly Revenue Growth (0.06) |
The market value of Agilent Technologies is measured differently than its book value, which is the value of Agilent that is recorded on the company's balance sheet. Investors also form their own opinion of Agilent Technologies' value that differs from its market value or its book value, called intrinsic value, which is Agilent Technologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agilent Technologies' market value can be influenced by many factors that don't directly affect Agilent Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Agilent Technologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Agilent Technologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agilent Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.